BioMarker Strategies is a tissue-based cancer diagnostics company that is developing the SnapPath® live tumor cell testing platform* to improve the treatment of cancer.

Supported with funding from the National Cancer Institute, the SnapPath® platform enables the development of ex vivo, next-generation predictive tests based on the activation of cell signaling pathways.  These profiles (called PathMap™ profiles) help guide targeted drug treatment selection, including drug combinations.

SnapPath® units are currently being utilized in human clinical and preclinical studies for advanced melanoma and other solid tumors. 

BioMarker Strategies
855 N.Wolfe St., Suite 623
Baltimore, MD 21205

Phone: 410-522-1008
Fax: 410-522-1009
info@biomarkerstrategies.com

*For Research Use Only (RUO). Not for use
in diagnostic procedures.